Although bortezomib treatment of myeloma cells displayed a statistically non-significant trend of TRAIL-R3 upregulation in patients without 8p21 deletion (1.46 fold, p = 0.0697), it did not have any impact on cells carrying the deletion (0.92 fold, p = 0.1855)(Fig 3C). This evidence concerns the gene TNFRSF10C and plasma cell myeloma.